Unlock stock picks and a broker-level newsfeed that powers Wall Street.

3 High Growth Tech Stocks Leading The US Market

In This Article:

Over the last 7 days, the United States market has risen by 4.1%, and over the past 12 months, it is up by 7.9%, with earnings forecasted to grow by 14% annually. In this environment of robust growth, identifying high-growth tech stocks that align with these positive trends can be key to capitalizing on potential opportunities in the market.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

20.29%

29.79%

★★★★★★

TG Therapeutics

26.06%

37.39%

★★★★★★

Travere Therapeutics

28.65%

66.06%

★★★★★★

Arcutis Biotherapeutics

26.11%

58.46%

★★★★★★

Alkami Technology

20.46%

85.16%

★★★★★★

Clene

62.08%

64.01%

★★★★★★

Alnylam Pharmaceuticals

23.08%

58.88%

★★★★★★

AVITA Medical

27.81%

55.17%

★★★★★★

Lumentum Holdings

21.34%

120.49%

★★★★★★

Ascendis Pharma

32.78%

59.70%

★★★★★★

Click here to see the full list of 234 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Gilead Sciences

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of $132.62 billion.

Operations: Gilead Sciences generates revenue primarily through the discovery, development, and commercialization of innovative medicines, amounting to $28.75 billion. The company's business model focuses on addressing unmet medical needs across various regions, including the United States and Europe.

Despite a challenging year with a net earnings decline of 91.5%, Gilead Sciences is poised for recovery, forecasting an impressive 22.9% annual earnings growth over the next three years. This growth trajectory significantly outpaces the broader US market's expected 13.9% increase. However, revenue growth projections remain modest at 3.5% annually, trailing the market average of 8.1%. Recent strategic developments include promising Phase 3 clinical trial results for Trodelvy in treating triple-negative breast cancer, potentially bolstering its oncology portfolio amid financial volatility marked by a substantial $9.3 billion one-off loss last year.

NasdaqGS:GILD Revenue and Expenses Breakdown as at Apr 2025
NasdaqGS:GILD Revenue and Expenses Breakdown as at Apr 2025

monday.com

Simply Wall St Growth Rating: ★★★★★☆

Overview: monday.com Ltd., along with its subsidiaries, develops software applications across various regions including the United States, Europe, the Middle East, Africa, and the United Kingdom, with a market cap of approximately $12.59 billion.